Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.58 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.58 |
| ▸ | PTGFR | P43088 | 3/20 | 0.56 |
| ▸ | TACR3 | P29371 | 3/20 | 0.56 |
| ▸ | TACR2 | P21452 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6447781 | 0.92 | ALDH1A1 (0.73) | ALDH1A1HPGDTP53LMNAMAPT | |
| SCHEMBL14523182 | 0.91 | LMNA (0.79) | ALDH1A1HPGDTP53LMNAMAPT | |
| SCHEMBL14523178 | 0.88 | ALDH1A1 (0.66) | ALDH1A1HPGDTP53LMNAMAPT | |
| SCHEMBL6448599 | 0.82 | ALDH1A1 (0.67) | ALDH1A1HPGDTP53LMNAMAPT | |
| SCHEMBL8226622 | 0.80 | ALDH1A1 (0.64) | ALDH1A1HPGDTP53LMNAMAPT | |
| SCHEMBL16553849 | 0.79 | LMNA (0.67) | ALDH1A1HPGDTP53LMNAMAPT | |
| SCHEMBL1582049 | 0.79 | ALDH1A1 (0.62) | ALDH1A1HPGDTP53LMNAMAPT | |
| SCHEMBL12564406 | 0.78 | DHODH (0.65) | ALDH1A1HPGDTP53LMNAKDM4E | |
| SCHEMBL1581468 | 0.75 | PDE10A (1.00) | LMNATSHRPDE10AKMT2ACYP2C19 | |
| SCHEMBL15503685 | 0.74 | KDM4E (1.00) | ALDH1A1HPGDTP53LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180110757-A1 | METHODS OF TREATING PRURITIS AND PAIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-04-26 | — | — | US | disclosed |
| US-7208502-B2 | Methods of treating conditions associated with an Edg-3 receptor | MANIV ENERGY CAPITAL (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208502-B2 | Methods of treating conditions associated with an Edg-3 receptor | MANIV ENERGY CAPITAL (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208502-B2 | Methods of treating conditions associated with an Edg-3 receptor | MANIV ENERGY CAPITAL (US) | 2007-04-24 | — | — | US | disclosed |
| US-20070032459-A1 | METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG-3 RECEPTOR | MANIV ENERGY CAPITAL | 2007-02-08 | — | — | US | disclosed |
| US-20070032459-A1 | METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG-3 RECEPTOR | MANIV ENERGY CAPITAL | 2007-02-08 | — | — | US | disclosed |
| US-20070032459-A1 | METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG-3 RECEPTOR | MANIV ENERGY CAPITAL | 2007-02-08 | — | — | US | disclosed |
| EP-1513522-A2 | METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG RECEPTOR | SRI INTERNATIONAL (US) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003062392-A2 | METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG RECEPTOR | CERETEK LLC (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032459-A1 | METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG-3 RECEPTOR | EDNRA, EDNRB, ESRRG | ALDH1A1 3227/4885HPGD 660/4885TP53 4527/4885 |
| US-20180110757-A1 | METHODS OF TREATING PRURITIS AND PAIN | CYSLTR2, LTB4R2, CYSLTR1 | ALDH1A1 2169/4885HPGD 1168/4885TP53 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.